SNN heads into its August 4 results with the lending market for its shares as tight as it has been all year.
The borrow story dominates the setup. Availability has collapsed to just 1.5% — meaning for every 100 shares already lent out, fewer than two remain available to borrow. That reading has been pinned near zero almost every session since early July, and the cost to borrow has nearly doubled over the past month to around 14.8%. Short interest itself has climbed roughly 8% over the past week and 11% over the past month, reaching around 4.1 million shares. The combination of rising demand for borrows and a near-empty lending pool is the defining tension ahead of the print. Options positioning has shifted meaningfully less bearish this week. The put/call ratio has pulled back to 1.00 from a 52-week high of 1.44 reached on July 21, drifting below its 20-day average of 1.10 — a notable reversal in defensive positioning over the final sessions before earnings. The stock itself gained 10% in the past month to close at $31.56, though it gave back 2.4% on Thursday alone.
The bull and bear cases are well-defined. Bulls point to accelerating reconstruction volumes, particularly a near-24% underlying growth in CORI-enabled procedures in the US, and management's expectation of a stronger second-half trading margin. The orthopedics segment's 5.5% underlying growth provides a credible growth narrative, and the dividend score ranks in the 83rd percentile of the universe — an unusually strong income signal for a mid-cap medical device company. Bears counter that the China business remains a structural drag, weighed down by inventory overhangs and regulatory uncertainty, while ROIC in orthopedics lags the company's own sports medicine and wound management units by a considerable margin. The most recent available analyst action — Canaccord Genuity trimming its target to $30 from $32 in May — leaves the stock trading above that floor, having rallied roughly 5% since that cut. The mean price target data appears stale and inconsistent with current price levels, so it has been set aside.
One institutional footnote adds texture. Bank of America nearly doubled its reported position to just over 20 million shares in its most recent filing, while Principal Global Investors trimmed by roughly 18.8 million shares — the two largest opposing moves among the top 15 holders. That divergence suggests a genuine ownership transition at the margin rather than consensus repositioning, and it runs alongside an insider buy from CEO Ajay Dhankhar in November 2025 — 18,460 shares at around $32.58 — that remains the most recent executive-level signal in the data.
Tuesday's earnings report will test whether the operational second-half recovery that management guided toward is materialising fast enough to justify a stock that has already priced in considerable good news — all while the borrow market leaves short sellers with almost no room to add pressure.
See the live data behind this article on ORTEX.
Open SNN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
